Abstract. Essential thrombocythemia (ET) is characterized by thrombotic and hemorrhagic events. The association of clinical characteristics of Chinese ET patients and additional sex combs like 1 (ASXL1) mutations in these patients has remained to be elucidated. In the present study, 72 newly diagnosed Chinese ET patients were enrolled to determine ASXL1 mutations. Mutations in ASXL1, Janus kinase (JAK)2, calreticulin (CALR) and myeloproliferative leukemia (MPL) genes were detected using Sanger sequencing, and data were statistically analyzed. The frequencies of ASXL1, JAK2 V617F, CALR and MPL W515 mutations in ET patients were 19.4% (14/72), 29.2% (21/72), 31.9% (23/72) and 0% (0/72), respectively. Of note, 28 ET patients (38.9%) were negative for JAK2, CALR and MPL mutations; these patients were classified as triple-negative (TN). The frequency of ASXL1 mutations in patients with JAK2 V617F, CALR and TN mutations was 23.8% (5/21), 21.7% (5/23) and 14.3%
Introduction
Essential thrombocythemia (ET), a clonal hematological disorder, is characterized by excessive proliferation of myeloid progenitor cells (1) . The absolute number of platelets in peripheral blood (PB) of ET patients is frequently >1,000x10 9 /l (2). The incidence of ET is ~41% worldwide (1, 2) . The most common symptoms are usually associated with thrombosis and hemorrhage. With regard to the clinical course, ET is relatively indolent; however, the majority of ET patients are unlikely to be completely cured. In addition, in <5% of affected patients, ET finally develops into acute myeloid leukemia (1) (2) (3) . The additional sex combs-like 1 (ASXL1) gene, located in chromosome 20q11, has been reported to be involved in epigenetic regulation and may be utilized for monitoring tumor stem or progenitor cell self-renewal or differentiation (4) (5) (6) . It has been identified that ASXL1 mutations are associated with hematologic disorders, including aplastic anemia, myeloproliferative neoplasms (MPNs), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia
ASXL1 mutations in Chinese patients
with essential thrombocythemia (CMML) (7) (8) (9) (10) (11) . In addition, in primary myelofibrosis (PMF) patients, ASXL1 mutations were identified to be correlated with a shorter overall survival (OS) (12, 13) . The frequencies of ASXL1 mutations were reported to be ~23, 5.6 and 3.5% in the MPN sub-types primary myelofibrosis (PMF), ET and polycythemia vera (PV), respectively (14) (15) (16) . Furthermore, ASXL1 mutations include not only point mutations, but frameshifts and nonsense mutations, of which the most common ones are frameshift mutations (c.1934dupG), accounting for nearly 50% of the reported ASXL1 mutations (14) (15) (16) . Furthermore, in patients with ET, the frequency of Janus kinase (JAK)2 V617F, calreticulin (CALR) and myeloproliferative leukemia (MPL) W515 mutations was reported to be ~50, <5 and ~11% in Western countries (17) (18) (19) (20) and ~60, ~30 and <5% in China, respectively (21) (22) (23) . However, the occurrence and precise roles of ASXL1 mutations in Chinese ET patients have remained elusive. In the present study, the occurrence of ASXL1 in 72 newly diagnosed ET patients was assessed and its clinical significance in ET was further investigated. Extraction and sequencing analysis of the PCR products was performed by Sangon Biotech (Shanghai, China). The Sanger DNA sequencing method was applied using an (ABI 3730XL; Applied Biosystems; Thermo Fisher Scientific, Inc.). The sequencing results were analyzed by Chromas 2.31 software (Technelysium Pty, Ltd., Brisbane, Qld, Australia) and the sequences were compared using Sequence scanner software version 1.0 (Applied Biosystems; Thermo Fisher Scientific, Inc.).
Materials and methods

Patients
Response criteria. Clinical response criteria for ET patients were according to those established by the European Leukemia Net consensus conference (2) . In brief, complete response (CR), partial response (PR) and no response (NR) were defined as follows: CR, PB PLT ≤400x10 9 /l, no disease-associated symptoms, normal spleen size on imaging and PB white blood cell (WBC) count ≤10x10 9 /l; PR, no fulfillment of CR criteria, PB PLT ≤600x10 9 /l or PLT decrease by >50% from baseline; NR, no fulfillment of CR and PR criteria.
Prognostic scoring for ET. Prognostic scoring for ET patients was according to the International Prognostic Scoring for Essential Thrombocythemia-thrombosis (IPSET-T) (24) . In brief, the scoring system, including several invariables (1 point for WBC count ≥11x10 9 /l or history of thrombosis and 2 points for age ≥60 years), was used to stratify patients into low-risk (0 point), intermediate-risk (1-2 points) or high-risk (3-4 points) groups.
Statistical analysis. Numeric variables are expressed as the median or mean ± standard deviation, while categorical variables were expressed as counts (n) and frequencies (%). Comparisons of enumeration data between different groups were performed using the chi-square test, while comparison of measurement data was performed using the Student's t-test or analysis of variance. Progression-free survival (PFS) was calculated by Kaplan-Meier survival analysis and respective curves were drawn. A multivariable Cox proportional hazards regression was used to model the duration and the incidence of PFS. All statistical analyses were performed with SPSS version 19.0 (IBM Corp., Armonk, NY, USA). All P-values are two-tailed and statistical significance was set as P<0.05. The risk factors of disease progression were analyzed by principal component analysis (PCA) and permutation multivariate analysis of variance (PERMANOVA), which is more robust regarding correlations and heterogeneous variance.
Results
Characteristics of patients and ET.
The clinical characteristics of the cohort of ET patients are summarized in Table II and those of ASXL1-mutant patients are listed in Table III Table IV ). In the entire cohort of ET patients, the occurrences of JAK2 V617F, CALR and MPL W515 mutations were 29.2% (21/72), 31.9% (23/72) and 0% (0/72), respectively, and 'triple-negative' (TN) ET patients accounted for 38.9% (28/72) of the entire cohort (Table V) . Patients with JAK2 V617F mutations had a significantly higher WBC count in the PB compared with that in TN patients (12.40±7.80 vs. 8.20±2.17x10 9 /l; P=0.02). However, the difference in the WBC count was insignificant between patients with JAK2 V617F and CALR mutations (12.40 vs. 8.82x10 9 /l; P=0.06). TN and CALR-mutant cohorts also exhibited an insignificant difference in WBC count (8.20 vs. 8.82x10 9 /l; P=0.457). Of note, TN patients had higher hemoglobin (HB) than CALR-mutant patients (140.37 vs. 129.29 g/l; P=0.074). The cut-off value of HB is ≥190 g/l CALR-mutant patients exhibited a higher PLT count than the JAK2 V617F-mutant cohort (787.91 vs. 562.17x10 9 /l; P=0.047). Compared with TN patients, CALR-mutant and JAK2 V617F-mutant patients had a significantly higher incidence in common symptoms, including dizziness, palpitation and chest congestion (39.1 and 38.1 vs. 14.3%; P=0.043 and 0.05, respectively). The occurrence of splenomegaly/hepatomegaly did not significantly differ among TN, CALR-mutant and JAK2 V617F-mutant patients (28.6 vs. 10.7%; P=0.221 and 28.6 vs. 8.7%; P=0.188; Table V ). However, a significant difference was present in the IPSET-T score and treatment response among the TN, CALR-mutant and JAK2 V617F-mutant patients (P=0.001 and P=0.015, respectively). There was no significant difference in the occurrence of thrombotic events among CARL-mutant, JAK2 V617F-mutant and TN cohorts (Table VI) . Table IV ). However, the frequencies of splenomegaly/hepatomegaly were similar between ASXL1-mutant and ASXL1-wt patients. In addition, ASXL1-mutant cohorts still exhibited a similar incidence in common clinical symptoms, including dizziness, palpitation and chest congestion, compared with ASXL1-wt patients (14.3 vs. 31%; P=0.356). There was no significant difference in the incidence in the history of coronary heart disease and hypertension between ASXL1-mutant and (Table III) . Of note, the ASXL1-mutant/TN cohort (median age and standard deviation, 51±18.17 years) was younger at diagnosis than the ASXL1-wt/JAK2V617F-mutant cohort (median age and standard deviation, 69±12.61; P=0.007). Furthermore, ASXL1-mutant/TN patients exhibited a higher number of PLT than ASXL1/JAK2 V617F-double mutant patients (data not shown). Values are expressed as the 'median; mean (standard deviation)' or as 'n (%)'. WBC, white blood cell; ASXL1, additional sex combs like 1; wt, wild-type; TN, triple-negative; JAK, Janus kinase; CALR, calreticulin; MPL, myeloproliferative leukemia. Values are expressed as n (%). CR, complete response; PR, partial response; NR, no response; TN, triple-negative; JAK, Janus kinase; CALR, calreticulin; IPSET-T, International Prognostic Scoring for ET thrombosis; ET, essential thrombocythemia.
PFS. It has been previously reported that in a proportion of patients ET may develop into MF, PV, MDS or AML (25) (26) (27) (28) (29) . Therefore, the present study further assessed this transformation in ET patients. Of note, ET did not transform to leukemia in any of the patients during the observation period. However, in 1 ET patient with and 4 patients without ASXL1 mutation, the disease transformed to PV, and in 1 patient with wild-type ASXL1, it transformed to MF. Statistical analysis indicated no significant difference in PFS between ASXL1-mutant and ASXL1-wt patients (P=0.590; Fig. 1A ). While in the further analysis, the PFS in the ASXL1-wt/JAK2 V617F-mutant group was significantly lower than the ASXL1-wt/TN group (P=0.026; Fig. 1B Fig. 2 ). No significant difference in disease progression was identified between ASXL1-mutant and ASXL1-wt cohorts (Table VII) .
Response to treatment. Next, the present study investigated whether ASXL1 mutations affect the response of ET patients to drug treatments. All patients enrolled in the study received either hydroxyurea, interferon-α or combination therapy of hydroxyurea and interferon-α. Statistical analyses indicated that the entire ASXL1-mutant cohort had a similar overall response rate (ORR) to the abovementioned treatments to that of the ASXL1-wt cohort. Additionally, the low-, intermediateand high-risk ASXL1-mutant groups also exhibited a similar ORR to the treatments compared with that of their wild-type counterparts. There was no statistically significant difference between the ASXL1-mutant and ASXL1-wt cohort in CR, PR or NR (Table IV) .
Discussion
Recently, ASXL1 mutations have been demonstrated in the majority of hematological diseases, including MDS, AML, MDS/MPN and CMML (8-13). In Western countries, the incidence of ASXL1 mutations in ET patients is ~5.6% (16) . However, the present study detected ASXL1 mutations in 19.4% of Chinese ET patients. This percentage is also higher than that reported by Shen et al (30) , who determined the occurrence of ASXL1 mutations in ET patients to be ~6.1%. This difference may be due to different genetics and environments. It has been indicated that ASXL1 gene mutations in hematological diseases include frameshift, point and nonsense mutations. Of note, frameshifts account for >50% of ASXL1 mutations. However, the present study indicated that the most frequent ASXL1 mutation in Chinese ET patients is c.G1954A with an incidence of 19.4%. In addition, point mutation [c.G1954A(p.Gly652Ser)] was the only mutation observed in the present study. The frameshift mutation, c.1934dupG, was not detected in the Chinese ET patients. The results of the present study were in accordance with those of Abdel-Wahab et al (31) , where the ASXL1 gene was sequenced from patients with multiple types of myeloid malignancies in paired tumor DNA and DNA extracted from buccal tissue. In the latter study, the frameshift mutation of ASXL1 [c.1934dupG(p.Gly646TrpfsX12)] was identified in an 8-bp guanine mononucleotide repeat sequence, and it was therefore speculated that the frameshift transformation was not a true somatic mutation, but an artifact of PCR amplification. Aforementioned mutation was no identified in the present study; this may be due to differences in genetics and the environments between the two studies. Indeed, the most commonly reported mutation of ASXL1 (c.1934dupG) was detected in >25% of healthy volunteers (31) , suggesting that the frameshift mutation in ASXL1 may not be an actual somatic mutation. Furthermore, another study revealed that ~0.2% (1/491) of normal control samples harbored a frameshift mutation, suggesting that this mutation may not be specific for ET patients (32) . The present study determined that compared with the ASXL1-wt group, ASXL1-mut patients had obvious propensities for thrombotic events, suggesting that an ASXL1 mutation is a factor associated with poor prognosis. However, due to the low death rate of ET patients enrolled in the present study, no difference in OS and PFS was identified between these two groups. As the precise functional role of ASXL1 in the pathogenesis of ET remains elusive, future studies are planned to uncover it using in vitro experiments. Furthermore, more clinical ET samples will be collected from multiple centers and analyzed in a future study.
Thrombohemorrhagic events are regarded to be among the most severe complications in ET patients (33) (34) (35) (36) . In the present study, ASXL1-mutant cohorts have demonstrated propensities for thrombotic events. Therefore, blocking of ASXL1 mutations may be a novel potential strategy to prevent the occurrence of thrombohemorrhagic events in ET patients in the clinic. Values are expressed as n/total (%). TN, triple-negative; JAK, Janus kinase; CALR, calreticulin; ASXL1, additional sex combs like 1; wt, wild-type.
